NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition

Yijian Gao, Yachao Zhang, Yujie Ma, Xiliang Li, Yu Wang, Huan Chen, Yingpeng Wan, Zhongming Huang, Weimin Liu, Pengfei Wang, Lidai Wang*, Chun-Sing Lee*, Shengliang Li*

*Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

1 Citation (Scopus)
12 Downloads (CityUHK Scholars)

Abstract

High-performance phototheranostics with combined photothermal therapy and photoacoustic imaging have been considered promising approaches for efficient cancer diagnosis and treatment. However, developing phototheranostic materials with efficient photothermal conversion efficiency (PCE), especially over the second near-infrared window (NIR-II, 1000–1700 nm), remains challenging. Herein, we report an ultraefficient NIR-II-activated nanomedicine with phototheranostic and vaccination capability for highly efficient in vivo tumor elimination and metastasis inhibition. The NIR-II nanomedicine of a semiconducting biradical oligomer with a motor-flexible design was demonstrated with a record-breaking PCE of 87% upon NIR-II excitation. This nanomedicine inherently features extraordinary photothermal stability, good biocompatibility, and excellent photoacoustic performance, contributing to high-contrast photoacoustic imaging in living mice and high-performance photothermal elimination of tumors. Moreover, a whole-cell vaccine based on a NIR-II nanomedicine with NIR-II-activated performance was further designed to remotely activate the antitumor immunologic memory and effectively inhibit tumor occurrence and metastasis in vivo, with good biosafety. Thus, this work paves a new avenue for designing NIR-II active semiconducting biradical materials as a promising theranostics platform and further promotes the development of NIR-II nanomedicine for personalized cancer treatment. © 2024 The Authors.
Original languageEnglish
Pages (from-to)1159-1170
Number of pages12
JournalActa Pharmaceutica Sinica B
Volume15
Issue number2
Online published20 Dec 2024
DOIs
Publication statusPublished - Feb 2025

Funding

This work was financially supported by the National Natural Science Foundation of China (No. 52173135), the Natural Science Foundation of Jiangsu Province (No. BK20231523, China), Jiangsu Specially Appointed Professorship, Leading Talents of Innovation and Entrepreneurship of Gusu (ZXL2022496, China), and the Suzhou Science and Technology Program (SKY2022039, China). Chun-Sing Lee thanks the support of the Research Grants Council of Hong Kong Special Administrative Region, General Research Fund (No. CityU 11300320, 11318322, China). Prof. Lidai Wang acknowledges support from the National Natural Science Foundation of China (No. 81627805) and the Research Grants Council of the Hong Kong Special Administrative Region (21205016, 11215817, 11101618, China). The authors would also like to acknowledge the project funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions and Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases.

Research Keywords

  • Breast carcinoma
  • Immunotherapy
  • Nanoparticles
  • NIR-II
  • Photothermal therapy
  • Semiconducting oligomer
  • Theranostics
  • Vaccine

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

Fingerprint

Dive into the research topics of 'NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition'. Together they form a unique fingerprint.

Cite this